Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era

Poonam Mathur*, Shyamasundaran Kottilil and Eleanor Wilson

Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA

Abstract

Ribavirin, once a staple of hepatitis C treatment, has significant drawbacks, including treatment-limiting side effects, the requirement for intensive laboratory monitoring, the need for frequent dose adjustments, and teratogenicity. These factors make it difficult to escalate ribavirin-based HCV treatment to most infected patients globally. Most studies have shown comparable response rates between ribavirin-inclusive and ribavirin-sparing regimens in uncomplicated patient populations. However, ribavirin is still used in the management of patients who have failed previous therapy as well as those with decompensated liver disease. In this review, we explore the evidence supporting the use of ribavirin in the current climate of hepatitis C treatment with oral combination direct-acting antiviral agents.

Citation of this article: Mathur P, Kottilil S, Wilson E. Use of ribavirin for hepatitis C treatment in the modern direct-acting antiviral era. J Clin Transl Hepatol 2018;6(4):1–7. doi: 10.14218/JCTH.2018.00007.

Introduction

Hepatitis C virus (HCV) infection affects 71 million people worldwide,1 and is a leading cause of death globally.2 Prior to the approval of oral combination direct-acting antivirals (DAAs) in 2014, all recommended HCV treatments included pegylated-interferon α (PEG-IFN) and ribavirin (RBV). In a recent systematic review and meta-analysis on hepatitis C treatment rates, however, it was estimated that only 25% of patients with chronic HCV infection worldwide were treated with these immune-based therapies.3 Treatment rates were likely limited by a number of factors, including the significant rates of side effects, the lack of adequate numbers of specialist providers, the fact that these therapies were contraindicated in patients with decompensated liver disease, and limited efficacy, particularly in patients with HIV/HCV co-infection or those with advanced liver disease.

Now, interferon-sparing combination DAA regimens have dramatically improved the treatment of HCV, with higher treatment efficiency, improved tolerability, and ease of dosing, with the majority of regimens available in once daily oral dosing.4 With the first published trials showing comparable response rates to combination DAA-based HCV treatments when given with and without RBV, it has been suggested that RBV-sparing regimens would improve treatment safety, tolerability, and adherence.5–7 However, there are several clinical scenarios and treatment regimens in which the addition of RBV is still recommended. Here, we discuss the data behind the current guidelines regarding the use of RBV in the revolutionary age of DAA-based treatment for HCV.

RBV

RBV is a synthetic triazole guanosine analog with activity against both DNA and RNA viruses.8,9 Suggested mechanisms of RBV include modulation of T helper-1 and -2 lymphocyte imbalance, depletion of cell guanosine triphosphate by inhibiting inosine monophosphate dehydrogenase, inhibiting viral RNA-dependent RNA polymerase, impairment of translation by preventing the capping of messenger viral RNA, and lethal viral mutagenesis (Fig. 1).8,9 Before the introduction of RBV, PEG-IFNα was the only available treatment for HCV, achieving low rates of sustained virologic response (SVR)—defined as absence of plasma HCV RNA in blood at 12 or 24 weeks after stopping treatment—of 15–20%.8 The addition of RBV to PEG-IFNα was shown to be superior to the use of PEG-IFNα alone,8,10–12 with an increased SVR rate of approximately 30%,10 among patients who received a regimen with RBV. The combination of PEG-IFNα and RBV also reduced the risk of post-treatment viral relapse.13 In a study by McHutchinson et al.,13 relapse rates were reduced by 38% in patients who received PEG-IFNα and RBV for 24 weeks and by 22% in those who received the regimen for 48 weeks.8 Due to higher efficacy and decreased rates of relapse compared to PEG-IFNα regimens alone, PEG-IFNα in combination with RBV became the standard of care for hepatitis C treatment in the 1990s and early 2000s.

Although RBV augments the effects of PEG-IFNα in HCV treatment, there are side effects associated with its use that significantly alter patient adherence and tolerance. Hemolytic anemia is the most significant adverse effect,12,14 afflicting up to 10% of patients,15 requiring laboratory monitoring of hemoglobin while on treatment, and frequent dose adjustments. Other side effects include pruritis, fatigue, and upper...
respiratory symptoms. Additionally, RBV is teratogenic, so women of child-bearing age who are on the medication or who have male partners taking the medication must use contraception.

**DAAs**

In May 2011, the FDA approved the protease inhibitors boceprevir and telaprevir, which were found to increase the rates of SVR 12 weeks after end of treatment (SVR12) when combined with PEG-IFNa and RBV, and the standard of care for hepatitis C treatment shifted to include one of these oral medications in combination with PEG-IFNa and RBV. Though the protease inhibitors greatly improved HCV treatment, their use was restricted by complicated dosing strategies requiring response-guided therapy and lead-in treatments, a low genetic barrier to resistance, and extensive drug-drug interactions. In 2013, the second generation of DAAs, which included the nucleotide analogue sofosbuvir (SOF), came to the forefront of HCV treatment. When combined with PEG-IFNa and RBV, treatment with SOF produced SVR12 rates in excess of 90% and the standard of care for hepatitis C treatment shifted to include one of these oral medications in combination with PEG-IFNa and RBV.

Among the GT1 treatment-naïve patients, a combination of DCV and SOF for 12 weeks produced SVR12 rates of 100% (41/41), compared to a 95% (39/41) SVR12 rate in those patients treated with DCV+SOF+RBV for 12 weeks. Among the GT1 patients who had failed previous treatment with a protease inhibitor, SVR12 rates were 100% (21/21) in patients treated with DCV+SOFA for 24 weeks, and 95% (19/21) for patients treated with DCV+SOFA+RBV for 24 weeks. Similarly, among patients with GT2 or GT3 infection, the addition of RBV did not result in a significantly higher virologic response rate; SVR12 was 100% (14/14) and 86% (12/14) for patients who were administered the RBV-sparing and RBV-inclusive regimens, respectively. The lower SVR rates seen with the RBV-inclusive regimens may reflect the high potency of DCV and SOF, indicating that RBV does not add to the potency of these oral DAAs.

A second study, LONESTAR, assessed treatment of GT1 infection in patients who were treatment-naïve or previously treated with a protease-inhibitor regimen. There were 19 treatment-naïve patients treated with LDV/SOF for 12 weeks, and 18 (95%) achieved SVR12. Among 21 patients who had failed previous treatment with a protease inhibitor, all (100%) achieved SVR12 after 12 weeks of LDV/SOF+RBV and 18 of 19 (95%) patients treated with LDV/SOF alone achieved SVR12. In a phase 3 study by Afdhal et al. (ION-1), 865 treatment-naïve patients with GT1 infection were randomized to receive LDV/SOF for 12 weeks, LDV/SOF+RBV for 12 weeks, LDV/SOF for 24 weeks, or LDV/SOF+RBV for 24 weeks. The rates of SVR12 were 99% in the group that received 12 weeks of LDV/SOF, 97% in the group that received 12 weeks of LDV/SOF+RBV, 98% in the group that received 24 weeks of LDV/SOF, and 99% in the group that received 24 weeks of LDV/SOF+RBV.

---

**Fig. 1. Proposed mechanisms of RBV.** (1) Immunomodulation favoring TH2 over the TH1 phenotype to enhance host immunity to the virus. (2) Competitive inhibition of IMPDH and subsequent depletion of the GTP pool, limiting replication of viral genomes and viral protein synthesis. (3) Inhibition of post- translational mRNA capping by directly inhibiting viral mRNA polymerase. (4) RBV acts as a mutagen in the target virus.

Abbreviations: IMPDH, inosine monophosphate dehydrogenase; RMP, ribavirin monophosphate; RDP, ribavirin diphosphate; RTP, ribavirin triphosphate; TH1, T helper 1; TH2, T helper 2.
Last, a phase 2b study\textsuperscript{24} evaluated the efficacy of a NS3/4A protease inhibitor (ABT-450) boosted with ritonavir (ABT-450/r), a non-nucleoside polymerase inhibitor (ABT-333), and a NS5A inhibitor (ABT-267) in various combinations with or without RBV. A total of 571 non-cirrhotic patients with GT1 infection (438 treatment-naïve and 133 treatment-experienced) underwent randomization to receive a regimen of ABT-450/r, combined with ABT-267 and/or ABT-333, for 8, 12 or 24 weeks and received at least one dose of therapy. All the subgroups but one also received RBV (dose determined according to body weight). When comparing the SVR\textsubscript{12} rate of the group that received all three drugs without RBV for 12 weeks and the group that received all three drugs with RBV for 12 weeks (89% vs. 96%, respectively), the contribution of RBV was not significant ($p = 0.09$). These studies suggest that adding RBV to DAAs does not result in significantly higher SVR\textsubscript{12} rates, and are summarized in Table 1.

Studies directly comparing DAAs are lacking, but a recent meta-analysis\textsuperscript{25} comparing different DAA-based regimens, with and without RBV, showed no improvement in treatment efficacy among DAA regimens that included RBV over those that were RBV-sparing. In addition, treatment regimens that incorporated RBV had a higher relative risk of adverse events, including anemia and fatigue. These studies support limiting the use of RBV, given the lack of increase in efficacy and more frequent toxicity. However, as we explore below, there are scenarios in which the addition of RBV to a DAA-based regimen might be warranted.

### Roles of RBV

There are several scenarios and patient groups in which the use of RBV is necessitated, as outlined below and summarized in Table 2.

#### Augmenting viral response in GT1 patients

RBV has been efficacious when used in regimens for both treatment-naive and treatment-experienced patients with GT1 infection. The daily fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD), for example, is an alternative regimen approved for treatment-naive GT1a and 1b patients with or without cirrhosis when given with weight-based RBV. The efficacy of RBV when added to ProD for HCV treatment, especially in GT1a patients, was demonstrated in three trials. In the SAPPHIRE-I trial,\textsuperscript{16} GT1 treatment-naive, non-cirrhotic patients with GT1 infection were treated with ProD+weight-based RBV for 12 weeks. Rates of response were more than 95% among the treatment-naive patients with GT1 infection. Additionally, in the PEARL-I\texttextsuperscript{17} study, Ferenci et al.\textsuperscript{27} evaluated the efficacy of patients treated with ProD with or without RBV. While there was no difference in rates of virologic failure with or without RBV among the GT1b patients, among the GT1a patients the rate of virologic failure was higher in the RBV-free group compared to the RBV group (7.8% vs. 2.0%). Last, for patients who had previously been unsuccessfully treated with PEG-IFNα and RBV, the SAPPHIRE-2 study\textsuperscript{28} examined the use of ProD with weight-based RBV in non-cirrhotic GT1 patients. In that study, patients were treated for 12 weeks and had an overall SVR\textsubscript{12} rate of 96%, with no differences noted when comparing response rates between subtypes.

RBV is also used to augment the SVR rate in patients who have baseline HCV resistance, when added to the fixed-dose combination of elbasvir (EBR) and grazoprevir (GZR). In the phase 3 C-EDGE trial,\textsuperscript{29} an international multicenter study, a 12- or 16-week course of EBR/GZR was given to treatment-naive patients infected with HCV genotypes 1, 4 or 6, some of whom had compensated cirrhosis. Of the 421 patients, 382 (91%) had GT1 infection. The SVR\textsubscript{12} was 92% in GT1a patients and 99% in GT1b patients. However, a post-hoc subanalysis revealed that the presence of baseline NS5A resistance-associated substitutions (RASs) was significantly associated with a decreased virologic response among GT1a patients; of 154 GT1a patients, 19 (12%) had baseline NS5A RASs, and of these 19, only 11 (58%) achieved SVR\textsubscript{12} compared to 133/135 (99%) patients without NS5A RASs.

Kwo et al.\textsuperscript{30} extrapolated data from the C-EDGE trial and found that among 58 patients who received EBR/GZR for 16 weeks with RBV, there were no virologic failures. Based on these analyses which suggest that prolonging treatment

---

### Table 1. HCV treatment studies and comparison of SVR rates of RBV-containing regimens

| Study       | Regimen                        | SVR Rate         |
|-------------|--------------------------------|------------------|
| Lawitz et al.\textsuperscript{50} | SOF+PEG-IFNα+RBV vs. Placebo+PEG-IFNα+RBV | 91% vs. 58%      |
| Jacobson et al.\textsuperscript{51} | SOF+RBV for 12 weeks vs. placebo | 78% vs. 0%       |
| ATOMIC\textsuperscript{52} | SOF+PEG-IFNα+RBV for 12 weeks vs. SOF+PEG-IFNα+RBV for 24 weeks | 90% vs. 93%      |
| Osinski et al.\textsuperscript{53} | SOF+weight-based RBV vs. SOF+low-dose RBV | 68% vs. 48%      |
| Pol et al.\textsuperscript{23} | PEG-IFNα+RBV vs. DCV+PEG-IFNα+RBV | 25% vs. 83%      |
| Sulkowski et al. (AI444040)\textsuperscript{7} | DCV+SOF for 12 weeks vs. DCV+SOF+RBV for 12 weeks | 100% vs. 95%      |
| LONESTAR\textsuperscript{6} | DCV+SOF for 24 weeks vs. DCV+SOF+RBV for 24 weeks | 100% vs. 95%      |
| ION-1\textsuperscript{5} | LDV+SOF for 12 weeks vs. LDV+SOF+RBV for 12 weeks | 95% vs. 100%      |
| Kowdley et al.\textsuperscript{24} | ABT-450/r+ABT-333+ABT-267 for 12 weeks vs. ABT-450/r+ABT-333 +ABT-267+RBV for 12 weeks | 89% vs. 96%      |
and adding RBV can overcome reduced EBR susceptibility, 
NS5A resistance testing is recommended for any GT1a patient 
in whom EBR/GZR therapy is considered. Use of RBV for 
the presence of baseline RASs is also recommended for treat-
ment-experienced patients with GT1 infection (with or without 
cirrhosis), based on the phase 2 C-SALVAGE study.\textsuperscript{31} In this study, 79 patients, 66 of whom (84%) had previously been 
treated with a regimen containing a protease-inhibitor, were 
given 12 weeks of EBR/GZR and weight-based RBV. At entry, 
34 patients (43%) harbored NS3A RASs, identified by popula-
tion sequencing. Response rates were high, with 76/79 
(96.2%) achieving SVR\textsubscript{12}, including 63/66 (95.5%) in patients 
with cirrhosis by providing a regimen option with a shorter 
duration.

### Augmenting response in treatment-experienced GT3 infection

In GT3 treatment-experienced patients, RBV is an important 
component of all currently recommended retreatment regi-
ments. In a study by Planko \textit{et al.},\textsuperscript{33} 96\% \((n = 26)\) of GT3 
patients with compensated cirrhosis who were PEG-IFN\textsubscript{x} 
and RBV-experienced were successfully retreated with a 
12-week duration of SOF/velpatasvir (VEL)+weight-based 
RBV, as compared to only 88\% of those who received 
SOF/VEL alone \((n = 26)\).

### Treatment of GT4 infection

PEARL-I was a randomized, open label trial that evaluated the 
efficacy of paritaprevir, ombitasvir, and ritonavir (PrO) with or 
without RBV in treatment-naive and treatment-experienced 
non-cirrhotic patients with GT4 infection.\textsuperscript{34} In 86 treat-
ment-naive patients, SVR\textsubscript{12} rates were 100\% \((42/42)\) for the RBV-containing regimen and 90.9\% \((40/44)\) for the RBV-free 
regimen. There were 49 treatment-experienced patients who received the RBV-containing regimen, and all achieved SVR\textsubscript{12}. 
The PEARL-I trial demonstrated the efficacy of RBV for viro-
logic cure in treatment-naive and treatment-experienced 
GT4 patients.

### Patients with decompensated cirrhosis

The ASTRAL-4\textsuperscript{35} study was the first to compare the use of 
DAs both with and without RBV in patients with decompens-
sated cirrhosis and demonstrated the utility of RBV in achieving 
high SVR\textsubscript{12} rates when combined with 12 weeks of SOF/VEL. 
Regardless of genotype, rates of viral response exceeded 
85\% when SOF/VEL was combined with RBV; this combina-
tion also resulted in the lowest rates of virologic failure for 
patients with GT3 (other studies have shown that SVR\textsubscript{12}

---

**Table 2. Indications/clinical scenarios and supporting studies which warrant use of ribavirin**

| Patient Population | Regimen | Study |
|--------------------|---------|-------|
| GT1a and GT1b, non-cirrhotic, treatment-naive | PrOD+RBV for 12 weeks | SAPPHIRE-I\textsuperscript{26} |
| GT1a, non-cirrhotic, treatment-naive | PrOD+RBV for 12 weeks | PEARL-IV\textsuperscript{27} |
| GT1, non-cirrhotic, treatment-experienced | PrOD+RBV for 12 weeks | SAPPHIRE-2\textsuperscript{28} |
| GT1a, with or without compensated cirrhosis, treatment-naive or treatment-experienced with protease inhibitor, with baseline NS3A RASs | EBR/GZR+RBV for 16 weeks | C-EDGE\textsuperscript{29,30} and C-SALVAGE\textsuperscript{31} |
| GT1, compensated cirrhosis, treatment-experienced with interferon | LDV/SOF+RBV for 12 weeks | SIRIUS\textsuperscript{32} |
| GT3, compensated cirrhosis, treatment-experienced with interferon | SOF/VEL+RBV for 12 weeks | Pianko \textit{et al.}\textsuperscript{33} |
| GT4, non-cirrhotic, treatment-naive and treatment-experienced | PrO+RBV for 12 weeks | PEARL-I\textsuperscript{34} |
| All genotypes, decompensated cirrhosis, treatment-naive and treatment-experienced (except with NS5A or NS5B inhibitor) | SOF/VEL+RBV for 12 weeks | ASTRAL-4\textsuperscript{35} |
| Post-liver transplant GT 1, 4, 5, 6 (including decompensated cirrhosis) | LDV/SOF+RBV for 12 weeks | SOLAR-1,\textsuperscript{36} HCV-TARGET,\textsuperscript{37} and Kwok \textit{et al.}\textsuperscript{38} |
| Post-liver transplant GT 2, 3 (compensated cirrhosis only) | DCV/SOF+RBV for 12 weeks | ALLY-1,\textsuperscript{39} and Fontana \textit{et al.}\textsuperscript{40} |
rates with GT3 are lower than rates for other genotypes). The SOF/VEL+RBV regimen was compared to SOF/VEL alone, each for 12 weeks, and SOF/VEL for 24 weeks. The response rate in the 12-week SOF/VEL+RBV arm was 94%, compared to 83% in SOF/VEL alone for 12 weeks and 86% in the SOF/VEL 24-week arm. Out of 267 patients treated in that study, 72 had pre-treatment NSSA RASs. Among these 72 patients, 64 (89%) had SVR12 compared to 169 of 183 patients (92%) who did not have pre-treatment NSSA RASs. In the SOF/VEL 24-week arm, the presence of NSSA RASs affected virologic cure, as the SVR12 among those with pre-treatment NSSA RASs was 90%, compared to a 98% SVR12 rate for those who had no pre-existing NSSA RASs. In addition, among the patients with GT1 who received SOF/VEL +RBV, the SVR12 rate was 100% for those who had NSSA RASs and 98% for those who did not, demonstrating that RBV is an important adjunct to increase the rate of virologic cure with a 12-week regimen in patients with baseline resistance. Based on the ASTRAL-4 study, the benefits of RBV in patients with decompensated cirrhosis include augmenting viral response, increasing the potency of HCV regimens in order to shorten treatment duration, and serving as a salvage treatment option for those patients in whom HCV treatment is of top priority in order to decrease risk of hepatocellular carcinoma and overall mortality.

**Patients with liver transplants**

For patients who are post-liver transplantation (with or without HCV treatment experience and/or compensated or decompensated cirrhosis) and infected with HCV 1, 4, 5 or 6, the only recommended, evidence-based regimen for treatment which includes RBV is in combination with LDV/SOF for 12 weeks. The evidence for use of RBV with LDV/SOF is provided by three studies. The SOLAR-1 study was a USA-based, phase 2, open-label study assessing LDV/SOF+RBV in patients with GT1 or 4 infection in two cohorts, one of which included patients who were post-liver transplant, with or without cirrhosis (Child-Pugh class A, B, or C). All of these patients were randomized to receive either 12 or 24 weeks of LDV/SOF with RBV. SVR12 rates among patients without cirrhosis and compensated cirrhosis were 96% and 98%, respectively. These rates were not affected by duration of treatment or cirrhosis status. In patients with Child-Pugh class B cirrhosis, the rates of SVR12 were similar with 12 weeks and 24 weeks of treatment (86% vs. 88%). Although there were lower SVR12 rates in patients with Child-Pugh class C disease (60% after 12 weeks of treatment and 75% after 24 weeks), this cohort was small (n = 9). Of note, 7 patients who had cirrhosis underwent liver transplant (4 before the end of treatment and 3 before post-treatment week 12). Six of 7 achieved SVR12; the seventh died of multiorgan failure and septic shock. SVR12 rates were similar despite duration of treatment (12 vs. 24 weeks) and only 4% of patients discontinued treatment due to adverse events from treatment drugs, this study led to the recommendation that 12 weeks of LDV/SOF+RBV is sufficient for patients after liver transplant. However, since all patients in the study received RBV, regardless of treatment duration, the role of RBV in higher SVR achievement could not be ascertained definitively from this study.

Second, the observational cohort HCV-TARGET included 347 patients with liver transplants, 279 of whom received LDV/SOF for 12 or 24 weeks. The SVR12 rates were 97% (152/157) for those who received RBV and 95% (116/122) in the group that did not take RBV. Patients who received RBV were more frequently GT1a, treatment-experienced, and had intact renal function. The rate of therapy discontinuation was only 1.3%. Third, a multicenter cohort analyzed response rates of LDV/SOF with or without RBV for 8, 12 or 24 weeks. Overall, 94% and 98% achieved SVR12 when receiving LDV/SOF without or with RBV, respectively. The SVR12 rate among patients who received 8 weeks of treatment was 86%, but did not differ greatly for 12 versus 24 weeks (94% vs. 95%). SVR12 rates in the RBV groups for 12 and 24 weeks was 97% and 100%, respectively. These studies suggest that high rates of SVR can be achieved without RBV; however, the addition of RBV may be considered for patients with an unfavorable baseline profile (i.e. cirrhosis, treatment-experienced).

For patients with GT2 or GT3 infection (with or without HCV treatment experience and/or compensated cirrhosis), the ALLY-1 trial and that by Fontana et al. demonstrate that DCV/SOF+RBV for 12 weeks is an effective regimen. In the ALLY-1 trial, DCV/SOF+RBV was given for 12 weeks to 60 patients, both treatment-naive and treatment-experienced, with Child-Pugh class A, B, or C cirrhosis after liver transplant. Eleven patients with GT3 were included in the trial; up to 83% (5/6) with advanced cirrhosis and 91% (10/11) with recurrent HCV after transplant achieved SVR12. In the study by Fontana et al., the overall SVR12 rate with DCV/SOF+RBV (for all genotypes) was 91% (70/77). Only 3 patients had GT2 or GT3, and they all received DCV/SOF+RBV and achieved SVR12. There have been no studies in patients with decompensated cirrhosis after liver transplant, so the AASLD/IDSA guidelines recommend using DCV/SOF+RBV for 12 weeks or SOF/VEL with RBV for 12 weeks.

**Resource-limited settings**

More than 80% of the worldwide HCV burden is in low- and middle-income countries; however, treatment escalation in these areas has been hindered by the high cost of DAAs in developing countries. A study by Iyengar et al. analyzed and compared prices of DAAs in 30 countries, noting that people in developing countries had more risk of paying higher adjusted prices than people in developed countries. Furthermore, they noted the price of generic SOF was more than the annual earnings for individuals in 12 of the 30 countries they analyzed. The World Health Organization (commonly known as WHO) estimates that in Ukraine, for example, a 4-week course of PEG-IFNα2b and RBV is $139, compared to $812 for 4 weeks of LDV/SOF. These facts highlight the conundrum that although DAAs are more efficacious and have fewer side effects than PEG-IFNα2b/RBV regimens, the cost of DAAs remains prohibitive for most patients who need to be treated worldwide. Therefore, in resource-limited settings or countries with a low gross domestic product, RBV (in combination with PEG-IFNα2b) may be the only accessible treatment option at present based on cost, particularly for easier to treat genotypes.

**Conclusions**

The WHO has established a goal to treat 80% of those with chronic HCV worldwide by 2030, an aspiration that, with the advent of combination DAA-based regimens, appears within reach for the first time. With the recent changes in the
guidelines and use of DAAs in the treatment of HCV, regimens have become more tolerable, effective, and less complicated, enabling HCV to be treated by primary care and midlevel providers, with minimal laboratory monitoring. Therefore, the use of RBV should be restricted to patients who have failed previous regimens and/or have decompensated cirrhosis, as there is data to support use in these populations. In both instances, as more and more new regimens become available, RBV’s utility will need to be revaluated, since RBV use is associated with significant anemia in decompensated patients and end-stage renal disease, and retreatment studies are relatively small and restricted to a few regimens. Addition of RBV to all DAA regimens to treat HCV patients is not advisable and may be hazardous. While there may be targets for future research. Curr Med Chem 2006;13:3351–3357. doi: 10.2174/092986706778773059. [15] Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related adverse events in the current era of HCV treatment, we recommend that the use of RBV should be limited to treatment in complicated patients who are managed under close supervision and should not be used to treat patients in primary care settings with uncomplicated HCV. Conflict of interest The authors have no conflict of interests related to this publication. Author contributions Responsible for drafting the article (PM, EW, involved in the critical revision of the article (EW, SK). All authors reviewed and approved the version of the article submitted.

References
[1] Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161–176. doi: 10.1016/S2468-1253(16)30181-9. [2] Stanaway JD, Flaxman AD, N晗havi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016;388:1081–1088. doi:10.1016/S0140-6736(13)63579-7. [3] Vuten P, Jin M, Le MH, Nguyen P, Trinh S, Huang JF, et al. Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis. PLoS One 2017;12:e0183851. doi:10.1371/journal.pone.0183851. [4] The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available from: http://www.atsl.org/upload/content/files/hcv-guidance-september-21-2017-d.pdf, accessed September 2017. [5] Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–1898. doi:10.1056/NEJMoa1402454. [6] Lawitz E, Poodord P, Fang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515–523. doi:10.1016/S0140-6736(13)62121-3. [7] Suikowsky MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanine T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211–221. doi:10.1056/NEJMoa1306218. [8] Mchutchion JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustigi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485–1492. doi:10.1056/NEJMoa98181191390101. [9] Testoni B, Leverro M, Durante D. Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question? Gut 2014;63:3–4. doi:10.1136/gutjnl-2013-304528. [10] Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalez FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:75–82. doi:10.1056/NEJMoa020047. [11] Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Clin Infect Dis 2004;40:346–355. doi:10.1086/372961. [12] Manns MP, McHutchison JG, Gordon SC, Rusi VK, Shiffman ML, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–965. doi:10.1016/S0140-6736(01)06102-5. [13] Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000;4:1–67. [14] Di Biseglie AM, Conjevaram HS, Fried MW, Sallie R, Park Y, Yurdyanit C, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897–903. doi:10.7326/0003-4813-123-199512020-00001. [15] Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related adverse events in the current era of HCV treatment, we recommend that the use of RBV should be limited to treatment in complicated patients who are managed under close supervision and should not be used to treat patients in primary care settings with uncomplicated HCV.

Mathur P. et al: Role of ribavirin for HCV treatment
Mathur P. et al: Role of ribavirin for HCV treatment

(SIRIUS). Lancet Infect Dis 2015;15:397–404. doi: 10.1016/S1473-3099(15)00520-2.

[33] Panko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: A randomized trial. Ann Intern Med 2015;163:809–817. doi: 10.7326/M15-1014.

[34] Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepnienska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015;385:2502–2509. doi: 10.1016/S0140-6736(15)00159-3.

[35] Curry MJ, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618–2628. doi: 10.1056/NEJMoa1512614.

[36] Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649–659. doi: 10.1053/j.gastro.2015.05.010.

[37] Saxena V, Khunagar V, Verna EC, Levitsky J, Brown RS Jr, Hassan MA, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology 2017;66:1090–1101. doi: 10.1002/hep.29258.

[38] Kwok RM, Ahn J, Schiano TD, Te HS, Potosky DR, Tierney A, et al. Sofosbuvir plus ledipasvir for recurrent hepatitis C in liver transplant recipients. Liver Transpl 2016;22:1536–1543. doi: 10.1002/lt.24614.

[39] Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Sofosbuvir with peginterferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63:1493–1505. doi: 10.1002/hep.28446.

[40] Fontana RJ, Brown RS Jr, Moreno-Zamora A, Pietra M, Joshi S, Londoño MC, et al. Daclatasvir combined with sofosbuvir or simprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl 2016;22:446–458. doi: 10.1002/lt.24416.

[41] Suthar AB, Harriss AD. A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med 2015;12:e1001795. doi: 10.1371/journal.pmed.1001795.

[42] Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012;54:1465–1472. doi: 10.1093/cid/css227.

[43] Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wikschor S, de Jongheer K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: An economic analysis. PLoS Med 2016;13:e1002032. doi: 10.1371/journal.pmed.1002032.

[44] Guidelines for the screening care and treatment of persons with chronic hepatitis C infection: Updated version. Available from: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0093400/.

[45] World Health Organization. Combining hepatitis B and C to reach elimination by 2030. Available from: http://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/, accessed May 2016.

[46] Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: A nonrandomized clinical trial. Ann Intern Med 2017;167:311–318. doi: 10.7326/M17-0118.

[47] Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmim S. Antiviral therapy in HCV-infected decompensated cirrhotics. Saudi J Gastroenterol 2010;16:310–314. doi: 10.4103/1319-3767.70632.

[48] Romero-Gómez M, Berenguer M, Molina E, Calleja JL. Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. J Hepatol 2013;59:1323–1330. doi: 10.1016/j.jhep.2013.07.014.

[49] Feld JJ, Jacobson IM, Sulkowski MS, Poonaf D, Tatsch F, Pawlotsky JM. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int 2017;37:5–18. doi: 10.1111/liv.13212.

[50] Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013;13:401–408. doi: 10.1016/S1473-3099(13)70033-1.

[51] Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867–1877. doi: 10.1056/NEJMoa1318454.

[52] Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with peginterferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381:2100–2107. doi: 10.1016/S0140-6736(13)60247-0.

[53] Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310:804–811. doi: 10.1001/jama.2013.109309.